Relationship between plasma fibrinogen levels and pulmonary function in the japanese population: The Takahata study

International Journal of Medical Sciences

Volumn 10, Issue 11, 2013, Pages 1530-1536

  Shibata, Yoko ^a   Abe, Shuichi ^a   Inoue, Sumito ^a   Igarashi, Akira ^a   Yamauchi, Keiko ^a   Aida, Yasuko ^a   Kishi, Hiroyuki ^a   Nunomiya, Keiko ^a   Nakano, Hiroshi ^a   Sato, Masamichi ^a   Sato, Kento ^a   Kimura, Tomomi ^a   Nemoto, Takako ^a   Watanabe, Tetsu ^a   Konta, Tsuneo ^a   Ueno, Yoshiyuki ^a   Kato, Takeo ^a   Kayama, Takamasa ^a   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Chronic obstructive pulmonary disease; Decline in FEV1; Fibrinogen; Pulmonary function; Smoker; Spirometry

Indexed keywords

FIBRINOGEN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; JAPANESE; LUNG DISEASE; LUNG FUNCTION; MALE; POPULATION RESEARCH; PREDICTIVE VALUE; SMOKING; SPIROMETRY;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; DECLINE IN FEV1; FIBRINOGEN; PULMONARY FUNCTION; SMOKER; SPIROMETRY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBRINOGEN; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; SEX FACTORS; SPIROMETRY; VITAL CAPACITY;

EID: 84884264960     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.7256     Document Type: Article

References (38)

1. [Internet] Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/
2. Barnes PJ. Celli BR Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33: 1165-85.
3. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 2011; 31: 494-9.
4. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012; 34: 43-62.
5. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2012.
6. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005; 128: 1475-82.
7. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest. 2000; 106: 1341-50.
8. Ploplis VA, Wilberding J, McLennan L, et al. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol. 2000; 157: 703-8.
9. Wilberding JA, Ploplis VA, McLennan L, et al. Development of pulmonary fibrosis in fibrinogen-deficient mice. Ann N Y Acad Sci. 2001; 936: 542-8.
10. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164: 1008-11.
11. Valvi D, Mannino DM, Mullerova H, et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two united states cohorts. Int J Chron Obstruct Pulmon Dis. 2012; 7: 173-82.
12. Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS One. 2010; 5: e11431.
13. Aida Y, Shibata Y, Osaka D, et al. The relationship between serum uric acid and spirometric values in participants in a health check: The Takahata study. Int J Med Sci. 2011; 8: 470-8.
14. Kishi H, Shibata Y, Osaka D, et al. FEV6 and FEV1/FEV6 in Japanese participants of the community-based annual health check: The Takahata study. Intern Med. 2011; 50: 87-93.
15. Nemoto T, Shibata Y, Osaka D, et al. Impact of cigarette smoking on maximal expiratory flows in a general population: The Takahata study. Intern Med. 2011; 50: 2547-55.
16. Nunomiya K, Shibata Y, Abe S, et al. Hyperhomocysteinaemia predicts the decline in pulmonary function in healthy male smokers. Eur Respir J. 2013; 42: 18-27.
17. Osaka D, Shibata Y, Abe S, et al. Relationship between habit of cigarette smoking and airflow limitation in healthy Japanese individuals: The Takahata study. Intern Med. 2010; 49: 1489-99.
18. Sato M, Shibata Y, Abe S, et al. Retrospective analysis of the relationship between decline in FEV1 and abdominal circumference in male smokers: The Takahata study. Int J Med Sci. 2013; 10: 1-7.
19. Shibata Y, Watanabe T, Osaka D, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: The Takahata study. Int J Med Sci. 2011; 8: 514-22.
20. The Committee of Pulmonary Physiology Japanese Respiratory Society. Guidelines for pulmonary function tests: Spirometry, flow-volume curve, diffusion capacity of the lung. Tokyo: The Committee of Pulmonary Physiology Japanese Respiratory Society, 2004.
21. [Internet] Ministry of Health Labour and Welfare. Measures for national health promotion. http://www.mhlw.go.jp/english/wp/wp-hw2/part2/p3_0024.pdf.
22. Mannino DM, Ford ES, Redd SC Obstructive and restrictive lung disease and markers of inflammation: Data from the Third National Health and Nutrition Examination. Am J Med. 2003; 114: 758-62.
23. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011; 365: 1184-92.
24. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA. 2005; 294: 1799-809.
25. Thomsen M, Dahl M, Lange P, et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186: 982-8.
26. Wolberg AS. Determinants of fibrin formation, structure, and function. Curr Opin Hematol. 2012; 19: 349-56.
27. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: A case-control study. BMC Med Genet. 2009; 10: 23.
28. Brehm JM, Hagiwara K, Tesfaigzi Y, et al. Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease. Thorax. 2011; 66: 1085-90.
29. Cho MH, Castaldi PJ, Wan ES, et al. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet. 2012; 21: 947-57.
30. Guo Y, Lin H, Gao K, et al. Genetic analysis of IREB2, FAM13A and XRCC5 variants in Chinese Han patients with chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2011; 415: 284-7.
31. Kong X, Cho MH, Anderson W, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med. 2011; 183: 43-9.
32. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): Identification of two major susceptibility loci. PLoS Genet. 2009; 5: e1000421.
33. Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet. 2010; 42: 36-44.
34. Wilk JB, Shrine NR, Loehr LR, et al. Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med. 2012; 186: 622-32.
35. Danik JS, Pare G, Chasman DI, et al. Novel loci, including those related to crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: The women's genome health study. Circ Cardiovasc Genet. 2009; 2: 134-41.
36. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003; 169: 203-14.
37. Polatli M, Cakir A, Cildag O, et al. Microalbuminuria, von willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis. 2008; 26: 97-102.
38. Munakata M, Asakawa M, Hamma Y, et al. [Present status of idiopathic interstitial pneumonia-from epidemiology to etiology]. Nihon Kyobu Shikkan Gakkai Zasshi. 1994; 32 Suppl: 187-92.